Literature DB >> 9848790

Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia.

T Miyata1, Y Ueda, Y Yamada, Y Izuhara, T Wada, M Jadoul, A Saito, K Kurokawa, C van Ypersele de Strihou.   

Abstract

Advanced glycation end product (AGE) formation is related to hyperglycemia in diabetes but not in uremia, because plasma AGE levels do not differ between diabetic and nondiabetic hemodialysis patients. The mechanism of this phenomenon remains elusive. Previously, it was suggested that elevation of AGE levels in uremia might result from the accumulation of unknown AGE precursors. The present study evaluates the in vitro generation of pentosidine, a well identified AGE structure. Plasma samples from healthy subjects and nondiabetic hemodialysis patients were incubated under air for several weeks. Pentosidine levels were determined at intervals by HPLC assay. Pentosidine rose to a much larger extent in uremic than in control plasma. Pentosidine yield, i.e., the change in pentosidine level between 0 and 4 wk divided by 28 d, averaged 0.172 nmol/ml per d in uremic versus 0.072 nmol/ml per d in control plasma (P < 0.01). The difference in pentosidine yield between uremic and control plasma was maintained in samples ultrafiltrated through a filter with a 5000-Da cutoff value and fortified with human serum albumin (0.099 versus 0.064 nmol/ml per d; P < 0.05). Pentosidine yield was higher in pre- than in postdialysis plasma samples (0.223 versus 0.153 nmol/ml per d; P < 0.05). These results suggest that a large fraction of the pentosidine precursors accumulated in uremic plasma have a lower than 5000 Da molecular weight. Addition of aminoguanidine and OPB-9195, which inhibit the Maillard reaction, lowered pentosidine yield in both uremic and control plasma. When ultrafiltrated plasma was exposed to 2,4-dinitrophenylhydrazine, the yield of hydrazones, formed by interaction with carbonyl groups, was markedly higher in uremic than in control plasma. These observations strongly suggest that the pentosidine precursors accumulated in uremic plasma are carbonyl compounds. These precursors are unrelated to glucose or ascorbic acid, whose concentration is either normal or lowered in uremic plasma. They are also unrelated to 3-deoxyglucosone, a glucose-derived dicarbonyl compound whose level is raised in uremic plasma: Its addition to normal plasma fails to increase pentosidine yield. This study reports an elevated level of reactive carbonyl compounds ("carbonyl stress") in uremic plasma. Most have a lower than 5000 Da molecular weight and are thus partly removed by hemodialysis. Their effect on pentosidine generation can be inhibited by aminoguanidine or OPB-9195. Carbonyl stress might contribute to AGE modification of proteins and thus to clinically relevant complications of uremia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9848790     DOI: 10.1681/ASN.V9122349

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  24 in total

1.  High plasma pentosidine level is accompanied with cardiovascular events in hemodialysis patients.

Authors:  Ryuichi Furuya; Hiromichi Kumagai; Toshio Miyata; Hirotaka Fukasawa; Shinsuke Isobe; Naoko Kinoshita; Akira Hishida
Journal:  Clin Exp Nephrol       Date:  2011-12-09       Impact factor: 2.801

2.  Immunohistochemical localization of advanced glycation end products in pinguecula.

Authors:  Yuichi Kaji; Tetsuro Oshika; Shiro Amano; Fumiki Okamoto; Wakako Koito; Seikoh Horiuchi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-07-21       Impact factor: 3.117

Review 3.  Present status and perspectives of bioartificial kidneys.

Authors:  Akira Saito; Tun Aung; Koji Sekiguchi; Yoshinobu Sato; Duc M Vu; Miho Inagaki; Genta Kanai; Reika Tanaka; Hajime Suzuki; Takatoshi Kakuta
Journal:  J Artif Organs       Date:  2006       Impact factor: 1.731

4.  GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients.

Authors:  Yi-Sheng Lin; Szu-Chun Hung; Yau-Huei Wei; Der-Cherng Tarng
Journal:  J Am Soc Nephrol       Date:  2008-12-03       Impact factor: 10.121

Review 5.  The aldo-keto reductase superfamily and its role in drug metabolism and detoxification.

Authors:  Oleg A Barski; Srinivas M Tipparaju; Aruni Bhatnagar
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

6.  Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes?

Authors:  Josephine M Forbes; Georgia Soldatos; Merlin C Thomas
Journal:  Clin Biochem Rev       Date:  2005-11

7.  Consequences of Advanced Glycation End Products Accumulation in Chronic Kidney Disease and Clinical Usefulness of Their Assessment Using a Non-invasive Technique - Skin Autofluorescence.

Authors:  Mihaela Oleniuc; Irina Secara; Mihai Onofriescu; Simona Hogas; Luminita Voroneanu; Dimitrie Siriopol; Adrian Covic
Journal:  Maedica (Buchar)       Date:  2011-10

Review 8.  Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease.

Authors:  Susan J Zieman; David A Kass
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology.

Authors:  Kazuho Honda; Chieko Hamada; Masaaki Nakayama; Masanobu Miyazaki; Ali M Sherif; Takashi Harada; Hiroshi Hirano
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-13       Impact factor: 8.237

10.  Multivariate analysis of matrix-assisted laser desorption/ionization mass spectrometric data related to glycoxidation products of human globins in nephropathic patients.

Authors:  Annunziata Lapolla; Eugenio Ragazzi; Barbara Andretta; Domenico Fedele; Michela Tubaro; Roberta Seraglia; Laura Molin; Pietro Traldi
Journal:  J Am Soc Mass Spectrom       Date:  2007-02-22       Impact factor: 3.109

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.